Last reviewed · How we verify
NCT04701060
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
Phase 2 trial testing Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w in Resectable Hepatocellular Carcinoma in 31 participants. Completed in 4 October 2024.
4 March 2024
Quick facts
| Lead sponsor | Tianjin Medical University Cancer Institute and Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 31 |
| Start date | 26 January 2021 |
| Primary completion | 4 March 2024 |
| Estimated completion | 4 October 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w — full drug profile →
Conditions studied
- Resectable Hepatocellular Carcinoma — all drugs for Resectable Hepatocellular Carcinoma →
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Who can join
Adults 18 to 75, any sex, with Resectable Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is A prospective, one-arm, phase II clinical study of Camrelizumab combined with apatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma.
Zhang N, Yang X, Piao M, Xun Z, et al · · 2024 · cited 69× · PMID 38355603 · DOI 10.1186/s40364-023-00535-z -
Advances of Targeted Therapy for Hepatocellular Carcinoma.
Niu M, Yi M, Li N, Wu K, et al · · 2021 · cited 39× · PMID 34381735 · DOI 10.3389/fonc.2021.719896 -
Mechanisms and Clinical Trials of Hepatocellular Carcinoma Immunotherapy.
Huang SL, Wang YM, Wang QY, Feng GG, et al · · 2021 · cited 24× · PMID 34306031 · DOI 10.3389/fgene.2021.691391 -
Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma.
Akula V, Chen L, Acikgoz Y, Klein K, et al · · 2025 · cited 7× · PMID 40050446 · DOI 10.1038/s41698-025-00846-4 -
Small-molecule-based targeted therapy in liver cancer.
Ming Y, Gong Y, Fu X, Ouyang X, et al · · 2024 · cited 6× · PMID 39113358 · DOI 10.1016/j.ymthe.2024.08.001 -
Current Perspectives on Perioperative Combination Therapy for Hepatocellular Carcinoma.
Nishio T, Yoh T, Nishino H, Ogiso S, et al · · 2025 · cited 5× · PMID 40528897 · DOI 10.1159/000546138 -
Insights in Molecular Therapies for Hepatocellular Carcinoma.
Heumann P, Albert A, Gülow K, Tümen D, et al · · 2024 · cited 5× · PMID 38791911 · DOI 10.3390/cancers16101831 -
Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma.
Crook CJ, Li D. · · 2023 · cited 5× · PMID 37688739 · DOI 10.1007/s11912-023-01455-9
Verify or expand the search:
- PubMed search for NCT04701060
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Resectable Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06569498 — Neoadjuvant Triple Therapy for Resectable HCC · recruiting
- NCT06524466 — Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma · Phase 2 · active not recruiting
- NCT05701488 — SIRT With Tremelimumab and Durvalumab for Resectable HCC · Phase 1 · recruiting
- NCT02379377 — 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant · Phase 1 · recruiting
- NCT04856046 — Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer · active not recruiting
Other Tianjin Medical University Cancer Institute and Hospital trials
Trials by the same sponsor.
- NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
- NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
- NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
- NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
- NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04701060 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
- Last refreshed: 3 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04701060.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing